3 years ago

Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: Post-hoc Analyses from the EMBODY Trials

William A. Wegener, Willem Koetse, Caroline Gordon, Xavier Mariette, Simon J. Bowman, Valérie Devauchelle-Pensec, Hendrika Bootsma, Anthony Shock, Sabine Bongardt, Catrinel Galateanu, David M. Goldenberg, Marga Oortgiesen, Jacques-Eric Gottenberg, Guy Meno-Tetang, Thomas Dörner, Gordana Kosutic, Holger Bartz
Objective EMBODY 1 (NCT01262365) and EMBODY 2 (NCT01261793) investigated the efficacy and safety of epratuzumab, a CD22-targeted humanized monoclonal IgG1 antibody, in patients with systemic lupus erythematosus (SLE). The studies showed no significant difference from placebo in primary or secondary clinical outcome measures, but did demonstrate B-cell-specific immunological activity. Methods Efficacy and safety of epratuzumab were compared between two patient subpopulations randomized in EMBODY 1 & 2: SLE patients with a diagnosis of associated Sjögren's syndrome (aSjS) and without aSjS (non-aSjS patients). BILAG total score, BICLA clinical response to treatment, biological markers (including B cells, IgG, IgM, and IgA), and safety were assessed. Results 1584 patients were randomized in EMBODY 1 and EMBODY 2; 113 patients were anti-SS-A positive, and had a diagnosis of aSjS, and 1375 patients (86.8%) had no diagnosis of aSjS (918 patients were randomized to epratuzumab and 457 to placebo). For aSjS, but not non-aSjS patients, a higher proportion of epratuzumab patients achieved a BICLA response and a reduction from baseline in BILAG total score. B-cell reduction was faster in aSjS patients. The sensitivity of B cells to epratuzumab as measured by mean concentration producing 50% of the maximum B-cell count depletion was lower for aSjS patients (9.47 μg/ml) vs the EMBODY total population (87.1 μg/ml). No difference in the frequency of adverse events from placebo was reported. Conclusion Patients with SLE and aSjS treated with epratuzumab showed improvements in SLE disease activity, which was associated with bioactivity, such as decreases in B cells and IgM. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/art.40425

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.